Expertise in
19
conditions

Rong F. Fu

No. 154, Anshan Road, 
Xiaobailou, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
19
conditions
No. 154, Anshan Road, 
Xiaobailou, CN 

Overview

Rong Fu practices practicing medicine in Xiaobailou, China.

Fu is highly rated in 19 conditions, according to our data. Their clinical expertise encompasses Aplastic Anemia, Anemia, Paroxysmal Cold Hemoglobinuria, Splenectomy, and Hepatectomy.

They are actively involved in clinical research, co-authoring 522 peer reviewed articles and participating in 7 clinical trials.

Locations

No. 154, Anshan Road, Xiaobailou, 300052, China
Other Locations
154 Anshan Street, Tianjin, 300052, China
154 Anshan Road, Tianjin, China
No.19 Yuquan Road, Shijingshan, 100049, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: APG2575
Study Phase: Phase 2
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 10, 2026
Intervention Type: Combination product
Study Drugs: Selinexor+Bortezomib+Dexamethasone, Bortezomib+Dexamethasone
Study Phase: Phase 3
A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
Enrollment Status: Completed
Publish Date: March 04, 2026
Clinical Outcome of Ixazomib (NINLARO®) Based Regimens in Chinese Patients With Multiple Myeloma Previously Receiving a Bortezomib/Carfilzomib-Based (re)Induction Regimen in Clinical Setting of Real World: An Open-Label, Single-Arm, Multicenter, Observation Study
Clinical Outcome of Ixazomib (NINLARO®) Based Regimens in Chinese Patients With Multiple Myeloma Previously Receiving a Bortezomib/Carfilzomib-Based (re)Induction Regimen in Clinical Setting of Real World: An Open-Label, Single-Arm, Multicenter, Observation Study
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2026
Intervention Type: Other
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 3
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2
A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
A Single-arm, Open-label, Multi-center Phase Ib/II Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
Enrollment Status: Terminated
Publish Date: November 29, 2023
Intervention Type: Drug
Study Drug: TQ-B3525
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

522 Total Publications

Three new lanostane-type triterpenoids with cytotoxic activity from the Ganoderma leucocontextum.
Three new lanostane-type triterpenoids with cytotoxic activity from the Ganoderma leucocontextum.
Journal: Natural product research
Published: July 01, 2026

Frequently Asked Questions about Rong F. Fu

Is Rong F. Fu a top-rated expert for Aplastic Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Rong F. Fu is classified as an Elite expert for Aplastic Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Rong F. Fu participate in research or clinical trials?

Yes. Rong F. Fu has published 522 articles and abstracts on conditions like Aplastic Anemia. You can view a list of Rong F. Fu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fu's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 75 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile